Scott M. Rocklage, PhD has been a managing partner at 5 AM Ventures since 2004. This was after he associated himself with the ventures as a partner in the year 2003.

In his academic journey,Dr. Scott Rocklage acquired his first degree in chemistry from the University of California, Berkely. He continued with his higher studies in chemistry at the Massachusetts Institute of Technology (MIT) where he acquired his PhD degree.

Richard R. Schrock who was a Nobel Prize winner in chemistry in the year 2005 gave Dr. Scott Rocklage an opportunity to conduct his doctorate research in his laboratory.

In more than thirty U.S. Patents the doctor’s, Boston MA office based, appears as either an inventor or a co-inventor. Being one of the best scholars in healthcare, Dr. Scott Rocklage has also managed to successfully make more than one hundred reviews on professional publications.

The doctor has many years of experience in healthcare. Dr. Rocklage has been in healthcare management for more than thirty years. Read more: Scott Racklage | Bloomberg and Scott Racklage | Crunchbase

This experience awarded him a Food and Drug Administration (FDA) approval of three US based New Drugs Applications. The three approvals include; Omniscantm, then teslascan(R) and lastly Cubicin(R). He has also made several clinical trials for new drugs.

In his career path, Dr. Scott Rocklage has served in several senior management positions. He has served as Cubist Pharmaceuticals Chairman and Chief Executive Officer. He has also worked as Nycomed Salutar Chief Executive Officer and President as well as Relypsa and Novira Board Chairman.

Dr. Scott Rocklage has also served as an executive chairman at Ilypsa which was acquired by Amgen and also Miikana which was acquired too by Entremed. The Doctor also served as an executive chairman of Semprus which was an acquisition of Teleflex. The doctor also served in research and development positions at catalytica and salutar.

The doctor is currently the chair of several Boards which includes; Rennovia, Kinestral and Cidara. He chairs Epirus and Pulmatrix Boards. In one of his interviews, Dr. Scott Rocklage considers the 5 AM Ventures an early stage company. This he says explains the use of the term 5 AM that is early in the morning.